SEARCH

SEARCH BY CITATION

References

  • 1
    Bloechl-Daum B, Deuson RR, Mavros P, Hansen M, Herrstedt J. Delayed nausea and vomiting continue to reduce patients' quality of life after highly and moderately emetogenic chemotherapy despite antiemetic treatment. J Clin Oncol. 2006; 24: 4472-4478.
  • 2
    Cohen L, de Moor CA, Eisenberg P, Ming EE, Hu H. Chemotherapy-induced nausea and vomiting: incidence and impact on patient quality of life at community oncology settings. Support Care Cancer. 2007; 15: 497-503.
  • 3
    Gagnon RC, King AG. Co-administration of ondansetron and casopitant mesylate, a novel NK-1 receptor antagonist, results in augmented anti-emetic activity in the ferret [abstract]. Proc Am Soc Clin Oncol. 2006; 24: 18S. Abstract 18608.
  • 4
    King A. Evaluation of the NK-1 receptor antagonist, GW679769, in cisplatin-induced acute and delayed emesis in the ferret [abstract]. Support Care Cancer. 2005; 13: 418. Abstract 04-030.
  • 5
    Chung F, Singla N, Singla S, Grenier A, Russo M. Casopitant for preventing postoperative vomiting in patients receiving opioids: pooled data analysis [abstract]. Paper presented at: 57th Annual Meeting of the American Society of Anesthesiologists; Madrid, Spain; October 13-17, 2006. Abstract A206.
  • 6
    Roila F, Rolski J, Ramlau R, Dediu M, Russo MW, Bandekar RR, Grunberg SM. Randomized, double-blind, dose-ranging trial of the oral neurokinin-1 receptor antagonist casopitant mesylate for the prevention of cisplatin-induced nausea and vomiting. Ann Oncol.In press.
  • 7
    GlaxoSmithKline. Data on file: GlaxoSmithKline Studies NKV10001 and NKV100787. Collegeville, Pa: GlaxoSmithKline; 2008.
  • 8
    Williams PL, Armitage P, Colton T. Trend tests for counts and proportions. Armitage P, Colton T, eds. Encyclopedia of Biostatistics. 6th ed. Chichester, United Kingdom: John Wiley & Sons; 1998: 4573-4584.
  • 9
    Gralla RJ, Osoba D, Kris MJ, et al. Recommendations for the use of antiemetics: evidence-based, clinical practice guidelines. J Clin Oncol. 1999; 17: 2971-2994.
  • 10
    Roila F, Donati D, Tamberi S, et al. Delayed emesis: incidence, pattern, prognostic factors and optimal treatment. Support Care Cancer. 2002; 10: 88-95.
  • 11
    Multinational Association of Supportive Care in Cancer. Consensus Conference on Antiemetic Therapy, March 29-31, 2004, Perugia, Italy. Latest Update: April 2007. Available at: http://www.mascc.org/media/Resource_centers/MASCC_Guidelines_Update.pdf Accessed August 8, 2007.
  • 12
    Kris MG, Hesketh PJ, Somerfield MR, et al. American Society of Clinical Oncology guideline for antiemetics in oncology: update 2006. J Clin Oncol. 2006; 24: 2932-2947.
  • 13
    Warr DG, Hesketh PJ, Gralla RJ, et al. Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer after moderately emetogenic chemotherapy. J Clin Oncol. 2005; 23: 2822-2830.